Clinical Assessment of Endothelial Dysfunction and Investigationof New Therapies in Cardiovascular Diseases

内皮功能障碍的临床评估和心血管疾病新疗法的研究

• 批准号: 22590786
• 负责人: SUGIYAMA Seigo
• 金额: $ 2.91万
• 依托单位: Kumamoto University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22590786/
• 关键词: 臨床心血管病態学; 血管内皮細胞障害; 冠動脈疾患; 心不全; 心血管イベント; 危険因子; 動脈硬化; 血管内皮機能; 糖尿病; vascular biology; 臨床研究; 循環器・高血圧; 血管内皮; ミトコンドリア; microparticles

We examined Reactive Hyperemia Peripheral Arterial Tonometry(RH-PAT) test and measurement of plasma levels of Endothelium-derived Microparticles(EMP) in patients suspected with coronary artery disease and heart failure patients inorder to assess vascular endothelial dysfunction clinically. We found CD144-EMP was anindependent prognostic factor for cardiovascular events in patients with heart failurewith reduced LVEF. We demonstrated the presence of coronary endothelial dysfunction andidentified distinctive clinical features in patients with coronary microvascular spasticangina. The vascular endothelial function assessed by RH-PAT test in patients with heartfailure with normal LVEF (HFNEF) was a significant and independent factor of the futurecardiovascular events. We demonstrated that the treatment by DPP-IV inhibitor(Sitagliptin); a new medicine for diabetes, improved the vascular endothelial functionand significantly inhibited atherosclerosis formation in the ApoE deficiency mouse, amouse model of atherosclerosis.

我们检查了反应性高血血管外周动脉渗透压（RH-PAT）测试，并在临床上临床评估血管内皮疾病的患者和心脏衰竭患者中，对内皮细胞衍生的微粒（EMP）的血浆水平的测量进行了评估评估血管内皮功能障碍。我们发现CD144-EMP是心力衰竭降低的LVEF患者心血管事件的非依赖性预后因素。我们证明了冠状动脉微血管痉挛患者的冠状动脉内皮功能障碍并识别出独特的临床特征。通过正常LVEF（HFNEF）的肝手术患者评估的血管内皮功能是未来性脑膜血管事件的重要且独立的因素。我们证明了DPP-IV抑制剂（西他列汀）的治疗；一种用于糖尿病的新药物，改善了血管内皮功能，并显着抑制了ApoE缺乏小鼠的动脉粥样硬化形成，即动脉粥样硬化的Amouse模型。

项目成果

Decreased Levels of Endogenous Plasma Active Glucagon Like Peptide-1 were Correlated with Endothelial Dysfunction in Patients with Coronary Risk Factors

内源性血浆活性胰高血糖素样肽 1 水平降低与患有冠状动脉危险因素的患者的内皮功能障碍相关

• 发表时间: 2015
• 作者: 松原純一;杉山正悟;小川久雄;松原 純一
• 通讯作者: 松原 純一

Beneficial Myocardial Effects of Immediate Rosuvastatin-therapy on Left Ventricular Remodeling and Functions after ST-elevated Myocardial Infarction Treated by Coronary Stenting

冠状动脉支架置入术治疗 ST 段抬高型心肌梗死后立即瑞舒伐他汀治疗对左心室重构和功能的有益作用

• 发表时间: 2012
• 作者: Chitose T;Sugiyama S;Shimomura H;Yamashita T;Hokamaki J;Tsunoda R;Ogawa H
• 通讯作者: Ogawa H

Digital Assessment of Endothelial Dysfunction in Patients with Coexistence of Coronary Artery Disease and Peripheral Arterial Disease-Effects of Cilostazol-

冠状动脉疾病和外周动脉疾病共存患者内皮功能障碍的数字化评估-西洛他唑的作用-

• 发表时间: 2011
• 作者: Maeda H;Matsuzawa Y;Sumida H;Sugiyama S;Ogawa H;Jinnouchi H
• 通讯作者: Jinnouchi H

パネルディスカッション：血管病変の非侵襲的評価法の有用性

小组讨论：血管病变无创评估方法的实用性

• 发表时间: 2012
• 作者: Kurokawa H;Sugiyama S;Matsubara J;Ohba K;Maeda H;Ogawa H;Hirofumi Maeda;Hiroaki Kusaka;Eiichi Akiyama;Junichi Matsubara;Hiroaki Kusaka;Koichiro Fujisue;Hirofumi Kurokawa;Hiroki Usuku;Masaaki Konishi;Eiichi Akiyama;Yoshihiro Hirata;Junichi Matsubara;Yasushi Matsuzawa;Yoshihiro Hirata;杉山 正悟;杉山 正悟
• 通讯作者: 杉山 正悟

Pentraxin 3 is a Significant Inflammatory Maker Predicting Future Cardiovascular Events in Patients with Heart Failure with Normal Left Ventricular Ejection Fraction

Pentraxin 3 是一种重要的炎症因子，可预测左心室射血分数正常的心力衰竭患者未来的心血管事件

• 发表时间: 2012
• 作者: Kurokawa H;Sugiyama S;Matsubara J;Ohba K;Maeda H;Ogawa H;Hirofumi Maeda;Hiroaki Kusaka;Eiichi Akiyama;Junichi Matsubara;Hiroaki Kusaka;Koichiro Fujisue;Hirofumi Kurokawa;Hiroki Usuku;Masaaki Konishi;Eiichi Akiyama;Yoshihiro Hirata;Junichi Matsubara
• 通讯作者: Junichi Matsubara